MX2021004976A - Anticuerpo fn14 antihumano. - Google Patents
Anticuerpo fn14 antihumano.Info
- Publication number
- MX2021004976A MX2021004976A MX2021004976A MX2021004976A MX2021004976A MX 2021004976 A MX2021004976 A MX 2021004976A MX 2021004976 A MX2021004976 A MX 2021004976A MX 2021004976 A MX2021004976 A MX 2021004976A MX 2021004976 A MX2021004976 A MX 2021004976A
- Authority
- MX
- Mexico
- Prior art keywords
- human
- antibody
- seq
- amino acid
- acid sequence
- Prior art date
Links
- 101100046559 Mus musculus Tnfrsf12a gene Proteins 0.000 abstract 3
- 101000648505 Homo sapiens Tumor necrosis factor receptor superfamily member 12A Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 102000055458 human TNFRSF12A Human genes 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 206010006895 Cachexia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Problema. Se proporciona un anticuerpo Fn14 antihumano que se une al Fn14 humano para inhibir una acción a través del Fn14 humano, evitando o tratar la caquexia por cáncer. Solución. Los inventores han realizado estudios sobre un anticuerpo Fn14 antihumano y han proporcionado un anticuerpo Fn14 antihumano que comprende una cadena pesada que consiste en la secuencia de aminoácidos de SEQ ID NO: 2 y una cadena ligera que consiste en la secuencia de aminoácidos de SEQ ID NO: 4.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018205995 | 2018-10-31 | ||
PCT/JP2019/042587 WO2020090892A1 (ja) | 2018-10-31 | 2019-10-30 | 抗ヒトFn14抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004976A true MX2021004976A (es) | 2021-06-15 |
Family
ID=70464144
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004976A MX2021004976A (es) | 2018-10-31 | 2019-10-30 | Anticuerpo fn14 antihumano. |
Country Status (17)
Country | Link |
---|---|
US (1) | US20210388096A1 (es) |
EP (1) | EP3875114A4 (es) |
JP (1) | JP7415939B2 (es) |
KR (1) | KR20210084473A (es) |
CN (1) | CN112930195B (es) |
AR (1) | AR123671A1 (es) |
AU (1) | AU2019369771A1 (es) |
BR (1) | BR112021008424A2 (es) |
CA (1) | CA3117930A1 (es) |
CO (1) | CO2021005768A2 (es) |
IL (1) | IL282650B1 (es) |
JO (1) | JOP20210093A1 (es) |
MA (1) | MA54097A (es) |
MX (1) | MX2021004976A (es) |
SG (1) | SG11202104463YA (es) |
WO (1) | WO2020090892A1 (es) |
ZA (1) | ZA202102879B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3207850A1 (en) | 2021-01-13 | 2022-07-21 | Astellas Pharma Inc. | Multispecific antibody bonding to actriia, actriib, and fn14 |
WO2023062848A1 (en) * | 2021-10-14 | 2023-04-20 | Astellas Pharma Inc. | Pharmaceutical composition comprising anti-human fnl4 antibody or antigen-binding fragment thereof for preventing or treating cancer |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
KR100337069B1 (ko) | 1993-03-11 | 2002-10-11 | 사이단호진가가쿠오요비겟세이리요호오겐큐쇼 | 항-hiv모노클로날항체 |
EP2298333A3 (en) * | 1999-12-20 | 2012-05-02 | Immunex Corporation | Tweak receptor |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CA2597485A1 (en) * | 2005-03-07 | 2006-09-14 | Genentech, Inc. | Methods and compositions for modulating tweak and fn14 activity |
LT2460831T (lt) * | 2005-05-27 | 2016-12-12 | Biogen Ma Inc. | Tweak rišantys antikūnai |
KR20100053607A (ko) * | 2007-08-03 | 2010-05-20 | 패시트 바이오테크 코포레이션 | 항-tweak 수용체 항체의 치료 용도 |
US20090324602A1 (en) * | 2008-05-15 | 2009-12-31 | Biogen Idec Ma Inc. | Anti-fn14 antibodies and uses thereof |
US8093006B2 (en) * | 2009-04-02 | 2012-01-10 | Hoffmann-La Roche Inc. | Antibodies against human tweak and uses thereof |
US8609818B2 (en) * | 2011-03-10 | 2013-12-17 | Omeros Corporation | Generation of anti-FN14 monoclonal antibodies by ex-vivo accelerated antibody evolution |
JP2014529597A (ja) | 2011-08-23 | 2014-11-13 | トランスバイオ リミテッド | Fn14結合性タンパク質及びその使用 |
JP2016000003A (ja) * | 2013-04-19 | 2016-01-07 | アステラス製薬株式会社 | 新規抗ヒトtweak抗体 |
AU2014280174A1 (en) * | 2013-06-14 | 2015-12-03 | Bayer Pharma Aktiengesellschaft | Anti-TWEAKR antibodies and uses thereof |
EP3019874B1 (en) * | 2013-07-09 | 2019-08-21 | The Translational Genomics Research Institute | Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14 |
-
2019
- 2019-10-30 CN CN201980071220.4A patent/CN112930195B/zh active Active
- 2019-10-30 MX MX2021004976A patent/MX2021004976A/es unknown
- 2019-10-30 IL IL282650A patent/IL282650B1/en unknown
- 2019-10-30 US US17/290,180 patent/US20210388096A1/en active Pending
- 2019-10-30 JO JOP/2021/0093A patent/JOP20210093A1/ar unknown
- 2019-10-30 KR KR1020217012606A patent/KR20210084473A/ko active Search and Examination
- 2019-10-30 MA MA054097A patent/MA54097A/fr unknown
- 2019-10-30 AR ARP190103146A patent/AR123671A1/es unknown
- 2019-10-30 JP JP2020553980A patent/JP7415939B2/ja active Active
- 2019-10-30 CA CA3117930A patent/CA3117930A1/en active Pending
- 2019-10-30 WO PCT/JP2019/042587 patent/WO2020090892A1/ja active Application Filing
- 2019-10-30 BR BR112021008424-0A patent/BR112021008424A2/pt unknown
- 2019-10-30 AU AU2019369771A patent/AU2019369771A1/en active Pending
- 2019-10-30 EP EP19880536.8A patent/EP3875114A4/en active Pending
- 2019-10-30 SG SG11202104463YA patent/SG11202104463YA/en unknown
-
2021
- 2021-04-29 ZA ZA2021/02879A patent/ZA202102879B/en unknown
- 2021-04-30 CO CONC2021/0005768A patent/CO2021005768A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR123671A1 (es) | 2023-01-04 |
BR112021008424A2 (pt) | 2021-09-28 |
WO2020090892A1 (ja) | 2020-05-07 |
IL282650B1 (en) | 2024-05-01 |
KR20210084473A (ko) | 2021-07-07 |
TW202035459A (zh) | 2020-10-01 |
SG11202104463YA (en) | 2021-05-28 |
JPWO2020090892A1 (ja) | 2021-09-24 |
CN112930195A (zh) | 2021-06-08 |
MA54097A (fr) | 2022-02-09 |
AU2019369771A1 (en) | 2021-06-03 |
IL282650A (en) | 2021-06-30 |
CA3117930A1 (en) | 2020-05-07 |
US20210388096A1 (en) | 2021-12-16 |
JOP20210093A1 (ar) | 2023-01-30 |
CN112930195B (zh) | 2024-03-19 |
JP7415939B2 (ja) | 2024-01-17 |
ZA202102879B (en) | 2022-10-26 |
EP3875114A1 (en) | 2021-09-08 |
EP3875114A4 (en) | 2022-08-10 |
CO2021005768A2 (es) | 2021-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ594682A (en) | Fully human antibodies specific to cadm1 | |
MX2021007006A (es) | Anticuerpo anti-calicreina-2 humanizado. | |
NZ743713A (en) | Human immunodeficiency virus neutralizing antibodies | |
MX2019007848A (es) | Anticuerpos anti-pd-1 y usos de los mismos. | |
PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
SG10201907161YA (en) | Antibodies directed against lymphocyte activation gene 3 (lag-3) | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
MY192822A (en) | An anti-ctla4 monoclonal antibody or antigen binding fragment thereof, a pharmaceutical composition and use | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
MX2019011986A (es) | Regiones constantes de igm humana modificadas para la modulacion de la funcion efectora de la citolisis dependiente de complemento referencia cruzada a solicitudes relacionadas. | |
NZ602780A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SI2579894T1 (en) | CGRP PROTITELESA | |
PE20141151A1 (es) | Proteinas de union al antigeno cd27l | |
MX2021012997A (es) | Anticuerpos anti-c5 humanizados bifuncionales y proteínas de fusión del factor h y usos de los mismos. | |
NZ595792A (en) | Antibodies specific to cadherin-17 | |
JOP20190103B1 (ar) | شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري | |
MX2017000615A (es) | Anticuerpo anti-tie 2 humano novedoso. | |
MX2021002710A (es) | Anticuerpos anti-c5 humanizados y usos de los mismos. | |
MX2020013324A (es) | Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos. | |
MX2022001111A (es) | Anticuerpo anti-pd-1 y uso farmaceutico del mismo. | |
NZ610091A (en) | Antibodies | |
MX2019008989A (es) | Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa. | |
MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
MX2021001516A (es) | Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores. | |
PH12018502293A1 (en) | Humanized anti-basigin antibodies and the use thereof |